1：World Journal of Surgical Oncology創(chuàng)刊于2003年，出版周期是Irregular，目前的影響因子是1.966，根據(jù)網(wǎng)友評價審稿速度大概是平均3月錄用比例是約75%。

中文簡介：《世界外科腫瘤學(xué)雜志》發(fā)表與外科腫瘤學(xué)及其相關(guān)學(xué)科的文章，如流行病學(xué)、癌癥研究、生物標志物、預(yù)防、病理學(xué)、放射學(xué)、癌癥治療、臨床試驗、多模態(tài)治療和分子生物學(xué)。重點放在原始研究文章上。該雜志還發(fā)表重要的臨床病例報告，以及對選定主題的平衡和及時的評論。腫瘤學(xué)是一個多學(xué)科的超級專業(yè)，外科腫瘤學(xué)是其中一個組成部分，尤其是實體瘤。世界各地的外科腫瘤學(xué)家都參與了從檢測癌癥病因的機制到治療和預(yù)防的研究。外科腫瘤學(xué)家的作用擴展到整個護理的連續(xù)性。隨著診斷和治療的不斷發(fā)展，外科腫瘤學(xué)家的角色也在不斷變化。因此，《世界外科腫瘤學(xué)雜志》旨在讓讀者了解最新的進展，這些進展最終將影響外科腫瘤學(xué)家的工作。開放存取《世界外科腫瘤學(xué)雜志》發(fā)表的所有文章在出版后立即免費永久在線訪問，不收取訂閱費或注冊障礙。有關(guān)開放式訪問的更多信息，請參見此處。

2：CANCER出版周期是Semimonthly，目前的影響因子是6.102，根據(jù)網(wǎng)友評價審稿速度大概是很快,2-3周錄用比例是較易。

英文簡介：Cancer, an international interdisciplinary journal of the American Cancer Society, publishes high-impact, peer-reviewed original articles and solicited content on the latest clinical research findings. Each issue of Cancer strives to be comprehensive, spanning the breadth of oncology disciplines and providing something for everyone involved in cancer research, risk reduction, treatment, and patient care.Aims and ScopeCancer seeks to impart highly relevant and timely information to a broad audience of oncology and related specialists in the field. Cancer accomplishes this objective by publishing original and review articles that facilitate the transfer of knowledge from the laboratory to the bedside; contribute to cancer prevention, early detection, diagnosis, cure, and rehabilitation; and diminish suffering from cancer. Cancer also publishes educational supplements on various topics that are of interest to a broad oncology audience..ReadershipOncologists and Oncology Specialists, Hematologists, Radiologists, Basic Science Researchers, Epidemiologists, Pathologists, Cancer Prevention Researchers, Urologists, Gynecologists, Gastroenterologists, Endocrinologists, Pulmonologists, and OtolaryngologistsKeywordsCancer, Diseases, Endocrine disorders, breast cancer, blood diseases, cancer statistics, cancer diagnosis

中文簡介：《癌癥》是美國癌癥學(xué)會的一份國際跨學(xué)科期刊，發(fā)表了影響深遠、同行評議的原創(chuàng)文章，并就最新的臨床研究成果征集內(nèi)容。癌癥的每一個問題都力求全面，跨越腫瘤學(xué)學(xué)科的廣度，為參與癌癥研究、風(fēng)險降低、治療和患者護理的每個人提供一些東西。目標和范圍癌癥致力于向廣大的腫瘤學(xué)和相關(guān)領(lǐng)域的專家提供高度相關(guān)和及時的信息。癌癥通過發(fā)表原創(chuàng)和評論文章來實現(xiàn)這一目標，這些文章有助于將知識從實驗室轉(zhuǎn)移到臨床；為癌癥預(yù)防、早期發(fā)現(xiàn)、診斷、治療和康復(fù)作出貢獻;減少癌癥帶來的痛苦�！栋┌Y》雜志還就廣大腫瘤學(xué)讀者感興趣的各種主題出版教育補刊。讀者腫瘤學(xué)家和腫瘤學(xué)專家、血液學(xué)家、放射科醫(yī)生、基礎(chǔ)科學(xué)研究人員、流行病學(xué)家、病理學(xué)家、癌癥預(yù)防研究人員、泌尿科醫(yī)生、婦科醫(yī)生、胃腸科醫(yī)生、內(nèi)分泌科醫(yī)生、肺科醫(yī)生和耳鼻喉科醫(yī)生關(guān)鍵字癌癥，疾病，內(nèi)分泌紊亂，乳腺癌，血液病，癌癥統(tǒng)計，癌癥診斷

3：Oncogenesis目前的影響因子是5.995，。

英文簡介：Oncogenesis is a peer-reviewed open access online journal that publishes full-length papers, reviews, and short communications exploring the molecular basis of cancer and related phenomena. It seeks to promote diverse and integrated areas of molecular biology, cell biology, oncology, and genetics.Oncogenesis seeks to encompass the breadth of the molecular biology of malignant change, and topics of particular interest include:ApoptosisCancer metabolismCell cycle and growth regulationCellular oncogenesCellular transformation and immortalizationDNA damage and repairMode of action of cancer therapeuticsMolecular oncologyNovel targeted therapiesSenescenceTumour suppressionVirus-induced oncogenesis

中文簡介：《腫瘤發(fā)生》是一本經(jīng)同行評審的開放訪問在線期刊，發(fā)表全文論文、評論和簡短的交流，探索癌癥和相關(guān)現(xiàn)象的分子基礎(chǔ)。它致力于促進分子生物學(xué)、細胞生物學(xué)、腫瘤學(xué)和遺傳學(xué)的多樣化和綜合領(lǐng)域。腫瘤發(fā)生試圖涵蓋惡性變化的分子生物學(xué)的廣度，特別感興趣的主題包括：細胞凋亡癌癥代謝細胞周期與生長調(diào)節(jié)細胞癌基因細胞轉(zhuǎn)化與永生DNA損傷與修復(fù)癌癥治療的作用方式分子腫瘤學(xué)新型靶向治療衰老腫瘤抑制病毒誘導(dǎo)的腫瘤發(fā)生

4：Photodiagnosis and Photodynamic Therapy創(chuàng)刊于2004年，出版周期是Quarterly，目前的影響因子是2.589，根據(jù)網(wǎng)友評價審稿速度大概是較慢,6-12周錄用比例是較易。

英文簡介：Official Journal of the European Platform for Photodynamic MedicineAffiliated with the International Photodynamic AssociationAlso affiliated with the British Medical Laser Association and the Polish Society for Photodynamic MedicineINDEXED in MEDLINE/PubMed, SciSearch/Science Citation Index Expanded, Current Contents/Clinical Medicine.Photodiagnosis and Photodynamic Therapy is an international journal for the dissemination of scientific knowledge and clinical developments of Photodiagnosis and Photodynamic Therapy in all medical specialties. The journal publishes original articles, review articles, case presentations, "how-to-do-it" articles, Letters to the Editor, short communications and relevant images with short descriptions. All submitted material is subject to a strict peer-review process.

中文簡介：歐洲光動力醫(yī)學(xué)平臺官方期刊隸屬于國際光動力協(xié)會也隸屬于英國醫(yī)學(xué)激光協(xié)會和波蘭光動力醫(yī)學(xué)會。在medline/pubmed中建立索引，擴展sciesearch/science引文索引，當(dāng)前內(nèi)容/臨床醫(yī)學(xué)。光診斷和光動力療法是一種國際性的雜志，旨在在所有醫(yī)學(xué)專業(yè)傳播光診斷和光動力療法的科學(xué)知識和臨床發(fā)展。該期刊發(fā)表原創(chuàng)文章、評論文章、案例陳述、“如何做到”文章、致編輯的信函、簡短的交流和相關(guān)圖片，并附有簡短的描述。所有提交的材料都要經(jīng)過嚴格的同行評審。

5：Current Oncology Reports創(chuàng)刊于1999年，目前的影響因子是3.949，根據(jù)網(wǎng)友評價審稿速度大概是較慢,6-12周。

英文簡介：Current Oncology Reports provides in-depth review articles contributed by international experts on the most significant developments in the field. By presenting clear, insightful, balanced reviews that emphasize recently published papers of major importance, the journal serves all those involved in the diagnosis, treatment, management, and prevention of cancer.

中文簡介：當(dāng)前腫瘤學(xué)報告提供了國際專家就該領(lǐng)域最重要進展所作的深入審查文章。通過提出清晰、有見地、平衡的評論，強調(diào)最近發(fā)表的重要論文，該雜志服務(wù)于所有涉及癌癥診斷、治療、管理和預(yù)防的人。

6：EJSO創(chuàng)刊于1985年，出版周期是Monthly，目前的影響因子是3.379，根據(jù)網(wǎng)友評價審稿速度大概是偏慢,4-8周錄用比例是容易。

英文簡介：Surgical Oncology has finally come of age and EJSO continues to play a major role in dissemination of information and knowledge relating to this surgical specialty. Published eight times a year, it presents original articles and state-of-the-art reviews of immediate interest to surgical oncologists. In addition, papers are published on chemotherapy, radiotherapy, epidemiology and pathology of cancer. The articles published also reflect the importance of communication between the laboratory and the clinician. Features Include: Clinical Trials Section Clinical Debate Section Early 'fast-track' publication Regular Reviews Education Section Research Areas Include: Epidemiology and preventive aspects of oncology Diagnosis, including imaging All aspects of therapy, including radiotherapy and chemotherapy Application of new equipment to surgical and clinical oncology Methods of assessing results of treatment Case reports that advance clinical and pathological knowledge Computing in relation to oncology EJSO is abstracted/indexed by: Index Medicus; EMBASE; ASCA; Science Citation Index.

中文簡介：外科腫瘤學(xué)終于成熟了，EJSO繼續(xù)在傳播與該外科相關(guān)的信息和知識方面發(fā)揮著重要作用。每年出版八次，向外科腫瘤學(xué)家提供最新的文章和最新的評論。此外，論文還發(fā)表在化療、放療、流行病學(xué)和癌癥病理學(xué)方面。發(fā)表的文章也反映了實驗室和臨床醫(yī)生之間交流的重要性。特點包括：臨床試驗部分臨床辯論部分早期“快速通道”出版物定期回顧教育部分研究領(lǐng)域包括：流行病學(xué)和腫瘤診斷預(yù)防方面，包括影像學(xué)治療的各個方面，包括放射治療和化療新設(shè)備在外科和臨床中的應(yīng)用。腫瘤學(xué)評估腫瘤治療病例報告結(jié)果的方法，推進了與腫瘤學(xué)EJSO相關(guān)的臨床和病理學(xué)知識計算，其摘要/索引方法為：索引Medicus；EMBASE；ASCA；科學(xué)引文索引。

7：TECHNOLOGY IN CANCER RESEARCH & TREATMENT創(chuàng)刊于2002年，出版周期是Bimonthly，目前的影響因子是1.481，根據(jù)網(wǎng)友評價審稿速度大概是平均2月錄用比例是約80%。

英文簡介：Technology in Cancer Research and Treatment welcomes manuscripts from active investigators involved in technologies devoted to early diagnosis, treatment, and palliation of cancer. The Journal will include both experimental and theoretical investigations. Among the topics that will be covered are MRI, including functional MRI, spiral CT, PET, optical spectroscopy, computer-aided reconstruction of tumors, computer-aided drug design, stereotactic radiosurgery, cryosurgery, brachytherapy, electroporation, photodynamic therapy, gene therapy, cancer vaccine, proteomics, and genomics, as they impact cancer research and treatment. Special emphasis will be given to non-invasive techniques. The Journal publishes original articles, express communications, opinion pieces, and timely reviews.

中文簡介：癌癥研究和治療技術(shù)歡迎從事癌癥早期診斷、治療和姑息治療技術(shù)的積極研究人員的手稿。該雜志將包括實驗和理論研究。將涉及的主題包括MRI，包括功能MRI、螺旋CT、PET、光譜學(xué)、腫瘤計算機輔助重建、計算機輔助藥物設(shè)計、立體定向放射外科、冷凍外科、近距離治療、電孔治療、光動力治療、基因治療、癌癥疫苗、蛋白質(zhì)組學(xué)和基因組學(xué)，因為它們影響癌癥的研究和治療。將特別強調(diào)非侵入性技術(shù)。該雜志發(fā)表原創(chuàng)文章，表達溝通，發(fā)表意見，并及時發(fā)表評論。

8：Therapeutic Advances in Medical Oncology目前的影響因子是5.67，。

英文簡介：Therapeutic Advances in Medical Oncology (TAM) is a peer-reviewed open access journal which focuses on pioneering efforts and innovative studies in the medical treatment of cancer. The journal is a member of the Committee on Publication Ethics (COPE).Therapeutic Advances in Medical Oncology delivers the highest quality peer-reviewed original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of cancer. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in medical oncology, providing an online forum for rapid dissemination of recent research and perspectives in this area.The editors welcome original research articles across all areas of oncology.The journal publishes original research articles and review articles primarily. Original research manuscripts may include laboratory, animal or human/clinical studies – all phases. Letters to the Editor and Case Reports will also be considered.Review articles include expert opinion/perspective reviews (including single-drug and drug class reviews), narrative reviews and therapeutic area reviews. Systematic reviews, meta-analyses, postmarketing and health economic and pharmacoeconomic reviews are also welcomed. The appropriate EQUATOR Network reporting guidelines should be followed (e.g. CONSORT for randomized, controlled trials and PRISMA for systematic reviews/meta-analyses). The journal endorses the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment. However, consistent with the AllTrials campaign, retrospectively registered trials will be considered if the justification for late registration is acceptable.The journal adheres to a blind review process in which the reviewer's name is routinely withheld from the author unless the reviewer requests a preference for their identity to be revealed. Manuscripts are reviewed by at least two referees; a first editorial decision is generally reached within 3 weeks of submission and Online First publication is usually within 3 weeks of Acceptance.

中文簡介：《腫瘤學(xué)治療進展》(TAM)是一份經(jīng)過同行評審的開放獲取期刊，專注于癌癥醫(yī)學(xué)治療方面的開拓性努力和創(chuàng)新研究。該雜志是出版?zhèn)惱砦瘑T會(COPE)的成員之一。醫(yī)學(xué)腫瘤學(xué)的治療進展提供了最高質(zhì)量的同行評審的原始研究文章、評論和學(xué)術(shù)評論，對癌癥醫(yī)學(xué)治療的開創(chuàng)性努力和創(chuàng)新性研究。該雜志具有很強的臨床和藥理學(xué)焦點，旨在吸引臨床和醫(yī)學(xué)腫瘤學(xué)研究人員的國際觀眾，為該領(lǐng)域的最新研究和觀點的快速傳播提供在線論壇。編輯們歡迎所有腫瘤學(xué)領(lǐng)域的原創(chuàng)研究文章。該雜志主要發(fā)表原創(chuàng)研究文章和評論文章。原始研究手稿可能包括實驗室、動物或人類/臨床研究——所有階段。給編輯的信和案例報告也將被考慮。審查文章包括專家意見/觀點審查（包括單藥和藥物類審查）、敘述性審查和治療領(lǐng)域?qū)彶�。系統(tǒng)綜述、薈萃分析、郵戳和健康經(jīng)濟和藥物經(jīng)濟評論也受到歡迎。應(yīng)遵循適當(dāng)?shù)某嗟谰W(wǎng)絡(luò)報告指南（如隨機對照試驗聯(lián)合會和系統(tǒng)回顧/薈萃分析Prisma）。該雜志贊同ICMje的要求，即臨床試驗應(yīng)在首次患者登記時或之前在世衛(wèi)組織批準的公共試驗登記處登記。但是，與所有試驗活動一致，如果可以接受延遲注冊的理由，將考慮回顧性注冊試驗。該雜志堅持一個盲目的審查過程，在這個過程中，審查者的名字通常不會透露給作者，除非審查者要求公開他們的身份。手稿由至少兩名評審人進行評審；第一次編輯決定通常在提交后3周內(nèi)作出，在線第一次出版通常在接受后3周內(nèi)作出。

9：CANCER LETTERS創(chuàng)刊于1975年，出版周期是Biweekly，目前的影響因子是6.508，根據(jù)網(wǎng)友評價審稿速度大概是約2.7個月錄用比例是約52.27%。

英文簡介：Carcinogenesis is a multi-disciplinary journal designed to bring together all the varied aspects of research which will ultimately lead to the prevention of cancer in man. the journal will publish full papers and short communications which warrant prompt publication in the areas of viral physical and chemical carcinogenesis and mutagenesis; factors modifying these processes such as DNA repair genetics and nutrition; metabolism of carcinogens; the mechanism of action of carcinogens and promoting agents; epidemiological studies; and the formation detection identification and quantification of environmental carcinogens. Accelerated papers are of important and timely work chosen by the editors which merit a fast review process followed by rapid publication (6 weeks). The editors may from time to time invite commentaries or short reviews.

中文簡介：《癌癥快報》是一本在癌癥研究的廣泛領(lǐng)域提供快速發(fā)表的簡短文章的雜志。該雜志重點介紹了癌癥的分子和細胞生物學(xué)、癌基因、致癌、輻射生物學(xué)、分子病理學(xué)、激素和癌癥、病毒腫瘤學(xué)、癌癥和轉(zhuǎn)移生物學(xué)、分子細胞遺傳學(xué)、流行病學(xué)和實驗治療學(xué)。出版的主要標準是多學(xué)科受眾的興趣。論文應(yīng)該簡短，但技術(shù)上健全，并由足夠的實驗細節(jié)證實。如果臨床論文有助于理解疾病的基本機制，將被接受。2001年1月起發(fā)表在《癌癥快報》上的論文將分為以下幾部分：致癌與癌癥預(yù)防、實驗治療、流行病學(xué)與分子流行病學(xué)、分子與細胞生物學(xué)、腫瘤生物學(xué)。敬請作者在向適當(dāng)?shù)木庉嬣k公室提交手稿時，選擇希望其手稿出現(xiàn)的部分（有關(guān)詳細信息，請參閱《作者指南》）。

10：Clinical & Translational Oncology創(chuàng)刊于2005年，出版周期是Monthly，目前的影響因子是2.441，根據(jù)網(wǎng)友評價審稿速度大概是平均2.2月錄用比例是約50%。

英文簡介：Clinical and Translational Oncology is an international journal devoted to fostering interaction between experimental and clinical oncology. It covers all aspects of research on cancer, from the more basic discoveries dealing with both cell and molecular biology of tumour cells, to the most advanced clinical assays of conventional and new drugs. In addition, the journal has a strong commitment to facilitating the transfer of knowledge from the basic laboratory to the clinical practice, with the publication of educational series devoted to closing the gap between molecular and clinical oncologists. Molecular biology of tumours, identification of biomarkers for cancer diagnosis, prognosis or prediction of treatment response, identification of new targets for cancer therapy, as well as development of new technologies for research and treatment of cancer are the major themes covered by both the educational series and research articles. A broad spectrum of subjects, including the molecular and cellular bases of disease, aetiology, pathophysiology, pathology, epidemiology, clinical features, and the diagnosis, prognosis and treatment of cancer, will be considered for publication.

中文簡介：《臨床與轉(zhuǎn)化腫瘤學(xué)》是一本致力于促進實驗?zāi)[瘤學(xué)與臨床腫瘤學(xué)相互作用的國際期刊。它涵蓋了癌癥研究的所有方面，從涉及腫瘤細胞和分子生物學(xué)的更基本的發(fā)現(xiàn)，到最先進的傳統(tǒng)和新藥的臨床檢測。此外，該雜志致力于促進從基礎(chǔ)實驗室到臨床實踐的知識轉(zhuǎn)移，出版了一系列致力于縮小分子腫瘤學(xué)家和臨床腫瘤學(xué)家之間差距的教育系列。腫瘤分子生物學(xué)、癌癥診斷生物標記物的識別、治療反應(yīng)的預(yù)后或預(yù)測、癌癥治療新靶點的識別以及癌癥研究和治療新技術(shù)的開發(fā)是教育系列和研究文章的主題。將考慮發(fā)表廣泛的主題，包括疾病的分子和細胞基礎(chǔ)、病因?qū)W、病理生理學(xué)、病理學(xué)、流行病學(xué)、臨床特征以及癌癥的診斷、預(yù)后和治療。

---

轉(zhuǎn)載請注明來自：http://www.jinnzone.com/qikanzhishi/77770.html